Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | glycylpeptide N tetradecanoyltransferase | 0.0175 | 0.1591 | 1 |
Mycobacterium tuberculosis | Naphthoate synthase MenB (dihydroxynaphthoic acid synthetase) (DHNA synthetase) | 0.0698 | 1 | 1 |
Trypanosoma cruzi | N-myristoyl transferase, putative | 0.0175 | 0.1591 | 0.5 |
Plasmodium vivax | glycylpeptide N-tetradecanoyltransferase, putative | 0.0175 | 0.1591 | 0.5 |
Echinococcus granulosus | glycylpeptide N tetradecanoyltransferase | 0.0175 | 0.1591 | 1 |
Trichomonas vaginalis | N-myristoyl transferase, putative | 0.0175 | 0.1591 | 1 |
Giardia lamblia | CDC72 | 0.0175 | 0.1591 | 0.5 |
Plasmodium falciparum | glycylpeptide N-tetradecanoyltransferase | 0.0175 | 0.1591 | 0.5 |
Mycobacterium ulcerans | naphthoate synthase | 0.0698 | 1 | 0.5 |
Leishmania major | N-myristoyl transferase, putative | 0.0175 | 0.1591 | 0.5 |
Trypanosoma cruzi | N-myristoyl transferase, putative | 0.0175 | 0.1591 | 0.5 |
Loa Loa (eye worm) | N-myristoyltransferase 2 | 0.0175 | 0.1591 | 1 |
Trypanosoma brucei | N-myristoyltransferase | 0.0175 | 0.1591 | 0.5 |
Brugia malayi | N-myristoyltransferase 2 | 0.0175 | 0.1591 | 1 |
Trypanosoma brucei | N-myristoyl transferase, putative | 0.0175 | 0.1591 | 0.5 |
Schistosoma mansoni | N-myristoyltransferase | 0.0175 | 0.1591 | 1 |
Entamoeba histolytica | glycylpeptide N-tetradecanoyltransferase, putative | 0.0175 | 0.1591 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3696 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 0.7079 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 2.9362 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.